Articles related to LUNG CANCER

The 2024 ASCO Annual Meeting reveals critical updates on lung and blood cancers, including promising phase 3 trial results and the innovative use of AI to reengage marginalized patients in cancer care.

Recent trials in NSCLC treatment reveal that perioperative immunotherapy, including combinations like nivolumab and chemotherapy, can significantly improve disease-free survival in early-stage resectable NSCLC.

In the CheckMate 77T trial, perioperative nivolumab plus chemotherapy followed by adjuvant nivolumab significantly improved event-free survival and pathological responses in patients with resectable NSCLC. The safety profile was consistent with known data, reinforcing nivolumab’s potential as a cornerstone in perioperative lung cancer therapy.

Explore the indicators of lung cancer, including persistent cough and unexplained weight loss, which may help in its early detection and improve patient outcomes.

In a recent phase 3 trial, alectinib has shown a notable improvement in both disease-free and CNS disease-free survival in patients with ALK-positive NSCLC, indicating a robust alternative to platinum-based chemotherapy regimens.

In a recent case, symptomatic joint pain and distinctive physical signs in a patient led to the identification of non-small-cell lung cancer, highlighting the critical role of thorough clinical assessment in revealing potential underlying malignancies.